Akbari Mohammad Esmaeil, Akbari Atieh, Khayamzadeh Maryam, Salmanian Reza, Akbari Mohammad
Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Academy of Medical Sciences, Islamic Republic of Iran, Tehran, Iran.
Breast Care (Basel). 2023 Feb;18(1):12-21. doi: 10.1159/000526746. Epub 2022 Sep 14.
This study aimed to estimate the 5- and 10-year survival rates of breast cancer in Iran.
This retrospective cohort study was performed in 2019 on breast cancer patients registered in the national cancer registry system of Iran during 2007-2014. The patients were contacted to collect their information and status (alive or dead). Age and pathological type of tumor were categorized into five groups, and the place of residence was divided into 13 regions. The Kaplan-Meier method and the Cox proportional hazards model were used for data analysis.
A total of 87,902 patients were diagnosed with breast cancer during the study, 22,307 of whom were followed-up. The 5- and 10-year survival rates of the patients were 80% and 69%, respectively. The mean age of the patients was 50.68 ± 12.76 years (median age, 49 years). About 2.3% of the patients were male. The 5- and 10-year survival rates were 69% and 50% in men, respectively. The highest survival rate was reported in the age group of 40-49 years, and the lowest rate was found in the age group of ≥70 years. Of all pathological types, 88% were found in the invasive ductal carcinoma group; the highest survival rate was reported in the noninvasive carcinoma group. The highest survival rate was reported in the Tehran region and the lowest in the Hamedan region. Based on the results, the Cox proportional hazards model, sex, age group, and pathological type were statistically significant differences.
This nationwide study performed on breast cancer patients indicated an improvement in the overall survival rate of these patients over the past years (the 5-year survival rate increased from 71% in 2011 to 80% in the present study), which might be attributed to advances in cancer management.
本研究旨在估算伊朗乳腺癌患者的5年和10年生存率。
这项回顾性队列研究于2019年对2007 - 2014年期间在伊朗国家癌症登记系统登记的乳腺癌患者进行。与患者取得联系以收集他们的信息和状态（存活或死亡）。肿瘤的年龄和病理类型分为五组，居住地分为13个地区。采用Kaplan - Meier方法和Cox比例风险模型进行数据分析。
研究期间共有87902例患者被诊断为乳腺癌，其中22307例接受了随访。患者的5年和10年生存率分别为80%和69%。患者的平均年龄为50.68±12.76岁（中位年龄49岁）。约2.3%的患者为男性。男性的5年和10年生存率分别为69%和50%。40 - 49岁年龄组的生存率最高，≥70岁年龄组的生存率最低。在所有病理类型中，88%为浸润性导管癌组；非浸润性癌组的生存率最高。德黑兰地区的生存率最高，哈马丹地区的生存率最低。基于结果，Cox比例风险模型、性别、年龄组和病理类型存在统计学显著差异。
这项针对乳腺癌患者的全国性研究表明，在过去几年中这些患者的总体生存率有所提高（5年生存率从2011年的71%提高到本研究中的80%），这可能归因于癌症管理方面的进步。
